EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Muneeb Ahmad Muneer, Muhammad Haris, Meerub Sajjad, Mahnoor Ahmed, Zoya Ehtsham, Lubaba Amaim, Yaseen Ali Khan, Aqib Mumtaz Akbar, Mariam Bukhari, Syed Kazim Raza Shah, Syed Tehseen Haider

Psychopharmacology Bulletin · 2026

DOI: 10.64719/pb.18519 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Muneeb Ahmad Muneer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Muneer, MBBS, Allama Iqbal Medical College, Lahore, Pakistan. Hauptthemen laut MEDLINE: Tourette Syndrome, Tetrabenazine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and vocal tics that can cause significant functional impairment. Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, has been evaluated in randomized controlled trials (RCTs) for tic reduction; however, individual studies have reported mixed results across clinical outcomes. We conducted a systematic review and meta-analysis to assess the efficacy and safety of deutetrabenazine compared with placebo in patients with Tourette syndrome.

Methods

A comprehensive literature search of PubMed, Embase, Scopus, and ClinicalTrials.gov was performed to identify randomized controlled trials evaluating deutetrabenazine versus placebo in Tourette syndrome up to October 2025. Primary outcomes included changes in Yale Global Tic Severity Scale (YGTSS), Tourette Syndrome–Clinical Global Impression (TS-CGI), Tourette Syndrome–Patient Global Impression of Improvement (TS-PGII), and Children and Adolescents–Gilles de la Tourette Syndrome Quality of Life (C&A-GTS-QOL). Secondary outcomes included depressive symptoms assessed by the Children’s Depression Inventory-2 (Parent Version) and the incidence of adverse events. Random-effects meta-analyses using restricted maximum likelihood estimation were conducted, with risk of bias assessed using the Cochrane Risk of Bias 2.0 tool.

Results

Three RCTs comprising 297 participants were included. Deutetrabenazine was associated with a statistically significant reduction in tic severity compared with placebo as measured by YGTSS (MD = −0.61; 95% CI: −1.15 to −0.07; p = 0.039), with no observed heterogeneity (I2 = 0%). No statistically significant differences were observed for TS-CGI, TS-PGII, C&A-GTS-QOL, or depressive symptoms. The risk of adverse events did not differ significantly between deutetrabenazine and placebo (RR = 1.18; 95% CI: 0.62 to 2.26; p = 0.39).

Conclusions

Deutetrabenazine demonstrates a modest but statistically significant reduction in tic severity in patients with Tourette syndrome, with a favorable safety profile. However, improvements in tic severity did not translate into significant benefits in global clinical impression, quality of life, or depressive symptoms. These findings support the role of deutetrabenazine as a potential adjunctive treatment for selected patients, while underscoring the importance of multimodal management strategies and further long-term studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tourette SyndromeTetrabenazineHumansRandomized Controlled Trials as TopicChildTreatment OutcomeAdolescentSeverity of Illness IndexQuality of LifeVesicular Monoamine Transport Proteins

Stichwörter der Autor:innen

Tourette syndromeVMAT2 inhibitordeutetrabenazinemeta-analysissystematic reviewtic disorders

Substanzen

TetrabenazinedeutetrabenazineVesicular Monoamine Transport Proteins

Autor:innen und Institutionen

  • Muneer, MBBS, Allama Iqbal Medical College, Lahore, Pakistan.
  • Haris, MBBS, Services Institute of Medical Sciences, Lahore, Pakistan.
  • Sajjad, MBBS, Allama Iqbal Medical College, Lahore, Pakistan.
  • Ahmed, MBBS, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Ehtsham, MBBS, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Amaim, MBBS, Allama Iqbal Medical College, Lahore, Pakistan.

Zitieren

APA

Muneer, M. A., Haris, M., Sajjad, M., Ahmed, M., Ehtsham, Z., Amaim, L., Khan, Y. A., Akbar, A. M., Bukhari, M., Shah, S. K. R., & Haider, S. T. (2026). Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.18519

Vancouver

Muneer MA, Haris M, Sajjad M, Ahmed M, Ehtsham Z, Amaim L, et al. Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.18519

BibTeX
@article{Muneer2026,
  author = {Muneer, Muneeb Ahmad and Haris, Muhammad and Sajjad, Meerub and Ahmed, Mahnoor and Ehtsham, Zoya and Amaim, Lubaba and Khan, Yaseen Ali and Akbar, Aqib Mumtaz and Bukhari, Mariam and Shah, Syed Kazim Raza and Haider, Syed Tehseen},
  title = {Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  doi = {10.64719/pb.18519}
}
Kostenlos starten →